High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- 7 January 2021
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 35 (2) , 485-493
Abstract
We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.Keywords
This publication has 16 references indexed in Scilit:
- Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammationLeukemia, 2020
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammationLeukemia, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.Journal of Clinical Oncology, 2020
- Risk assessment of venous thromboembolism and bleeding in COVID-19 patientsResearch Square, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetLeukemia, 2018
- A life‐threatening ruxolitinib discontinuation syndromeAmerican Journal of Hematology, 2017
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With MyelofibrosisMayo Clinic Proceedings, 2011
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983